Sloan Sheldon's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed May 1, 2026
- Accession no.
- 0002038798-26-000004
- Filed
- May 1, 2026
- Trade date
- May 1, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.60M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sloan SheldonCIK 0002038798 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | MOption exerciseAcquired | +78,333 | $27.46 | +$2,151,024.18 | 78,333 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −21,306 | $69.53 | −$1,481,406.18 | 57,027 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −19,656 | $70.61 | −$1,387,910.16 | 37,371 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −8,777 | $71.56 | −$628,082.12 | 28,594 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −12,777 | $72.94 | −$931,954.38 | 15,817 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −10,358 | $73.74 | −$763,798.92 | 5,459 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −5,059 | $74.60 | −$377,401.4 | 400 | Direct | |
| May 1, 2026 | Common Stock | SSaleDisposed | −400 | $75.37 | −$30,148 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | MOption exerciseDisposed | −78,333 | $0.00 | $0 | 321,667 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.